文献速递围术期管理与 ERAS

减重手术后合并症缓解的处方药使用情况:基于人群的队列研究

Prescription drug usage as measure of comorbidity resolution after bariatric surgery: a population-based cohort study.
PubMed 文献 · Surg Endosc · 2023-07-25

该研究基于加拿大曼尼托巴省人群数据库,纳入2013至2019年间接受胃旁路术或袖状胃切除术的1184例患者,分析术前5年及术后5年的门诊处方配药数据以评估合并症缓解情况。结果显示降糖药、降脂药及降压药使用持续减少,而抗抑郁药、甲状腺药物使用稳定,质子泵抑制剂和阿片类药物术后1年增加后回落至基线。

要点

  • 代谢综合征相关药物(降糖、降脂、降压)处方在减重术后长期持续减少。
  • 抗抑郁药、SSRI及甲状腺药物处方在术后保持稳定。
  • 质子泵抑制剂和阿片类药物术后1年增加,随后回落至基线水平。

核心结论

  • 减重手术后代谢综合征相关药物处方持续减少并维持至长期随访。

研究设计与样本

  • 基于人群的队列研究,纳入曼尼托巴省2013至2019年接受胃旁路术或袖状胃切除术的1184例患者,获取术前5年及术后5年的处方配药数据。

主要发现

  • 抗抑郁药和选择性5-羟色胺再摄取抑制剂(SSRI)是最常用处方类别,与甲状腺药物一样术后使用稳定。
  • 质子泵抑制剂和阿片类药物术后1年增加,随后回落至基线。
  • 葡萄糖和降脂药物(包括他汀类、双胍类、磺脲类和胰岛素)使用减少。
  • 抗高血压药(包括ACE抑制剂、钙通道阻滞剂、血管紧张素受体阻滞剂、噻嗪类和β受体阻滞剂)同样减少。

临床怎么用

  • 可利用省级处方数据库长期追踪减重术后合并症缓解情况,减少自报偏倚。
  • 术后应关注质子泵抑制剂和阿片类药物的短期使用增加,并及时评估调整。
  • 代谢综合征相关药物减少可作为合并症缓解的客观指标之一。

局限性

  • 需进一步研究阐明药物使用变化对患者生活质量和医疗支出的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Obesity is a chronic and progressive disease associated with significant morbidity, mortality, and health-care costs. Bariatric surgery is the most effective intervention for sustainable weight loss and resolution of obesity-related comorbidities. Studies examining comorbidity resolution largely rely on individual self-reported outcomes and electronic record reviews. We present a population-based study looking at prescription medication utilization before and after bariatric surgery as a measure of comorbidity resolution. METHODS: All patients enrolled in the Center for Metabolic and Bariatric Surgery who underwent either gastric bypass or sleeve gastrectomy between 2013 and 2019 in Manitoba were included. Demographic information, follow up, and outpatient prescription dispensation data were obtained from the Manitoba Population Research Data Repository housed at the Manitoba Centre for Health Policy for 5 years pre- and post-surgery. RESULTS: A total of 1184 patients were included. Antidepressants and selective serotonin reuptake inhibitors were the most commonly prescribed classes, and along with thyroid medication, utilization remained stable after bariatric surgery. Proton pump inhibitors and opioid class drugs increased at 1 year after surgery then returned to baseline. Glucose and lipid-lowering medications, including statins, biguanides, sulfonylureas, and insulin, were decreased. Antihypertensives, including ACE inhibitors, calcium channel blockers, angiotensin receptors blockers, thiazides, and beta blockers, similarly decreased. CONCLUSION: This is the first Canadian study employing a provincial-wide prescription database to measure long-term comorbidity resolution after bariatric surgery. The use of administrative data eliminates potential biases and inaccuracies in follow up and self-reported outcomes. Consistent with the literature, prescriptions for the treatment of metabolic syndrome all decreased and were sustained at long-term follow up. Further studies are needed to delineate the effects of altered pharmaceutical utilization on patient quality of life and health-care expenditures.

来源:Surg Endosc,查看原文。版权归原作者所有。

引用

  1. Wu TCH, He W, Dharmasena I, et al. Prescription drug usage as measure of comorbidity resolution after bariatric surgery: a population-based cohort study. Surg Endosc. 2023. PMID: 37491659. doi:10.1007/s00464-023-10294-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。